ECC 2015: NETTER-1 trial showed rare cancer responded unusually well to new treatment - European Medical Journal

ECC 2015: NETTER-1 trial showed rare cancer responded unusually well to new treatment

Oncology

NETTER-1, a phase 3 clinical trial, evaluated Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in patients with Grade 1–2 metastatic midgut neuroendocrine tumours (NETs). The results to date showed 177Lu-DOTATATE provided a clinically meaningful and statistically significant increase in progression-free survival (PFS) in the patients treated with 177Lu-DOTATATE.

Presented at the European Cancer Conference (ECC) 2015 by Philippe Ruszniewski, MD, of Beaujon Hospital, Clichy, France.

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>